Vinh Pham
Neurology · Toledo, OHNPI 1043847056
Payments from drug & device makers
Across 121 payments — averaging $154.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- AbbVie$511
- UCB, Inc.$379
- SK Life Science, Inc.$279
- Bristol Myers Squibb$176
- AstraZeneca$143
- plus $536 from 13 others
What the payments were for
- Grants$15,00080%
- Travel & lodging$1,2767%
- Food & beverage$2,38713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $16,639 |
| AbbVie | 21 | $511 |
| UCB, Inc. | 24 | $379 |
| SK Life Science, Inc. | 14 | $279 |
| Bristol Myers Squibb | 11 | $176 |
| AstraZeneca(2 entities) | 7 | $143 |
| Neurelis, Inc. | 6 | $112 |
| Merz Pharmaceuticals, LLC | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Genentech USA, Inc. | 2 | $47 |
| Biogen | 3 | $44 |
| Pyros Pharmaceuticals, Inc. | 1 | $43 |
| Catalyst Pharmaceuticals, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $19 |
| CSL Behring | 1 | $17 |
| Pfizer | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA PC$15,000
- PERCEPT PC BRAINSENSE$1,229
- VYALEV$105
How this compares
$18,663 in reported general payments places this provider in the 70th percentile of 702 neurology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 11 | $12,771 |
| Lacosamide | 24 | $2,656 |
| Levetiracetam | 49 | $1,607 |
| Donepezil Hcl | 22 | $1,229 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 18 | $1,131 |
| Gabapentin | 32 | $498 |
| Lamotrigine | 19 | $466 |
| Propranolol Hcl | 15 | $156 |
| Clonazepam | 14 | $61 |
| Topiramate | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $279 | $12,77111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 702 neurology providers in Ohio.
Other neurology in Toledo
- Lawrence ElmerToledo$1.5M
- Mouhammad JumaaToledo$1.1M
- Howard SchechtToledo$564K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.